Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 11/20 | 0.57 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 6/20 | 0.46 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12011230 | 0.78 | RPS6KA5 (0.57) | RPS6KA5CDC7CDK2METRPS6KA4 | |
| SCHEMBL13378058 | 0.76 | RPS6KA5 (0.59) | RPS6KA5CDC7CDK2METRPS6KA4 | |
| SCHEMBL29509090 | 0.74 | RPS6KA5 (0.57) | RPS6KA5CDC7CDK2METRPS6KA4 | |
| SCHEMBL1472997 | 0.74 | RPS6KA5 (0.57) | RPS6KA5CDC7CDK2METRPS6KA4 | |
| SCHEMBL256322 | 0.74 | RPS6KA5 (0.57) | RPS6KA5CDC7CDK2METRPS6KA4 | |
| SCHEMBL1446137 | 0.74 | RPS6KA5 (0.57) | RPS6KA5CDC7CDK2METRPS6KA4 | |
| SCHEMBL27987760 | 0.74 | RPS6KA5 (0.57) | RPS6KA5CDC7CDK2METRPS6KA4 | |
| SCHEMBL10197264 | 0.74 | RPS6KA5 (0.57) | RPS6KA5CDC7CDK2METRPS6KA4 | |
| Quinoline SCHEMBL925691 | 0.74 | ALDH1A1 (0.59) | RPS6KA5CDC7CDK2 | |
| SCHEMBL10309417 | 0.72 | MAPT (0.48) | RPS6KA5CDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-20230348852-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| WO-2017035753-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 无锡双良生物科技有限公司 | 2017-03-09 | — | — | WO | disclosed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| EP-2332909-A1 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | Astex Therapeutics Limited (GB) | 2011-06-15 | — | — | EP | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348852-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | B2M, EPAS1, LATS2 | RPS6KA5 4091/4885CDC7 2164/4885CDK2 268/4885 |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | RPS6KA5 2119/4885CDC7 3387/4885CDK2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.